MedAlliance

Established in 2008 by Jeffrey B. Jump, MedAlliance SA is a Swiss-based medical technology company focused on developing and commercializing drug-device combination products for treating coronary and peripheral artery disease. Mr. Jump, who serves as Chairman and CEO, leveraged his extensive experience in the medical device industry, including a 13-year tenure as CEO of Biosensors International, to identify shortcomings in existing stent technologies. This insight led to the company's mission: to create a treatment that delivers a therapeutic drug without leaving a permanent metal implant behind.

The company's core product is the SELUTION SLR™ (Sustained Limus Release), a drug-eluting balloon (DEB). This device addresses atherosclerosis, the hardening of arteries, by delivering the anti-restenotic drug sirolimus to the affected vessel during an angioplasty procedure. Its technology features unique MicroReservoirs—a blend of biodegradable polymer and sirolimus—that coat the balloon. When the balloon is inflated within the artery, the proprietary Cell Adherent Technology (CAT™) ensures the MicroReservoirs adhere to the vessel wall, providing a controlled and sustained drug release for up to 90 days. This approach is designed to prevent restenosis, or the re-narrowing of the artery, a common complication with permanent metal stents.

MedAlliance primarily serves interventional cardiologists and vascular surgeons in hospitals and clinics worldwide. The company achieved significant regulatory milestones, including CE Mark approvals in 2020 for both peripheral and coronary artery disease treatment. It also became the first DEB company to receive multiple 'Breakthrough Device Designations' and Investigational Device Exemption (IDE) approvals from the U.S. FDA for various indications, including in-stent restenosis and below-the-knee lesions. In October 2023, the company's trajectory culminated in a landmark acquisition by Cordis, a global leader in interventional vascular technology. The deal, valued at up to $1.135 billion, involved an upfront payment and future milestone-based payments, reflecting the significant market potential of the SELUTION SLR™ technology. The acquisition provides MedAlliance with Cordis's extensive global sales and distribution network, aiming to accelerate the worldwide adoption of its stent-less angioplasty solution.

Keywords: MedAlliance, SELUTION SLR, drug-eluting balloon, sirolimus, Cordis acquisition, Jeffrey B. Jump, interventional cardiology, peripheral artery disease, coronary artery disease, medical device, cardiovascular technology, sustained drug release, MicroReservoirs, Cell Adherent Technology, stentless angioplasty, anti-restenotic, FDA IDE approval, CE Mark, vascular surgery, medtech exit